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ABSTRACT
Adenoid cystic carcinoma (ACC) is among the most common salivary gland 
malignancies, and is notorious for its unpredictable clinical course with frequent 
local recurrences and metastatic spread. However, the molecular mechanisms for 
metastatic spread are poorly understood. This malignancy is known to frequently 
harbor gene fusions involving MYB, MYBL1, and NFIB, and to have a low mutational 
burden. Most studies have focused on primary tumors to understand the biology of 
ACC, but this has not revealed a genetic cause for metastatic dissemination in the 
majority of cases. Hence, other molecular mechanisms are likely to be involved. Here, 
we characterize the genetic and microRNA expressional landscape of primary ACC and 
corresponding metastatic lesions from 11 patients. FISH demonstrated preservation 
of MYB aberrations between primary tumors and metastases, and targeted next-
generation sequencing identified mutations exclusive for the metastatic lesions 
in 3/11 cases (27.3%). Global microRNA profiling identified several differentially 
expressed miRNAs between primary ACC and metastases as compared to normal 
salivary gland tissue. Interestingly, individual tumor pairs differed in miRNA 
profile, but there was no general difference between primary ACCs and metastases. 
Collectively, we show that MYB and NFIB aberrations are consistently preserved in 
ACC metastatic lesions, and that additional mutations included in the 50-gene hotspot 
panel used are infrequently acquired by the metastatic lesions. In contrast, tumor 
pairs differ in microRNA expression and our data suggest that they are heterogeneous 
according to their microRNA profile. This adds an additional layer to the complex 
process of ACC metastatic spread.
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INTRODUCTION
Metastatic dissemination is a fundamental process 
in the progression of malignant disease, and is the cause 
of the majority of cancer-related deaths [1]. Despite 
this the mechanisms underlying the acquired ability 
of cells to metastasize are poorly understood [2]. As a 
consequence, the ability to accurately predict, prevent, 
and treat metastatic disease remain a major challenge in 
prognostication and oncological treatment. However, 
while most studies explore primary tumors in the search 
for molecular answers to these challenges, identification 
of discordances between primary tumors and metastases 
have the potential to reveal key drivers of metastatic 
progression.
Adenoid cystic carcinoma (ACC) is among the most 
frequent and enigmatic malignancies of the salivary gland 
[3]. It is characterized by an unpredictable clinical course 
with frequent local recurrences, late onset of metastases 
mainly to the lungs and liver and, consequently, an often 
fatal outcome [4, 5]. The genetics of primary ACC have 
been extensively explored, which has resulted in the 
identification of recurrent gene fusions involving the 
MYB, MYBL1, and NFIB genes and frequent mutations in 
NOTCH pathway genes [6–8]. So far, these characteristic 
genetic profiles have provided a valuable insight into 
the biology of ACC but have not contributed to the 
understanding of metastatic dissemination in the majority 
of patients [9, 10]. Recently, spatial genetic differences 
within and between paired primary ACCs and metastases 
have been reported, but only few and diverse mutations 
were found in coding regions [11]. While this study 
demonstrates the relatively quiet genome of primary 
ACC is preserved in metastases, it provides explanations 
to metastatic spread in a subset of cases but at the same 
time raises the question as to whether additional molecular 
mechanisms are involved in metastatic spread of ACC.
MicroRNAs (miRNAs) are short non-coding 
RNAs ~22 nucleotides in length, functioning as potent 
post-transcriptional regulators of gene expression [12]. 
MiRNAs have been shown to be implicated in numerous 
cancers and to be of prognostic value, including in 
salivary gland ACC [13, 14]. Several in vitro studies 
have characterized the effects of miRNAs on primary 
and metastatic ACC cell lines, but the findings have 
recently been discredited due to contamination of all 
of these cultures with various non-ACC cell lines [15]. 
Hence, reliable data from human ACC samples is highly 
warranted.
To further explore the molecular background for 
ACC dissemination, we performed fluorescence in situ 
hybridization (FISH), targeted next-generation sequencing 
(NGS), and global miRNA expression profiling in paired 
samples of primary and metastatic ACC.
RESULTS
Clinicopathologic characteristics
Patients included six males and five females with 
primary ACC of various head and neck sites (Table 1, 
Figure 1A). Radical surgical removal of the primary lesion 
was performed in 4/11 primary tumors. All metastases 
were metachronous and were from brain (case 1), lung 
(cases 2–9), and liver (case 5, 10, and 11), with latency 
from surgery of the primary lesion to metastatic spread 
ranging from 7–119 months (median: 60.5) (Figure 1B–
1D). Radical surgical removal of the metastatic lesion 
was performed in 9/11 patients. Median follow-up was 
46 months (range: 2–97). At the end of follow-up, five 
patients had died of disseminated disease, three were 
alive with disease, and three had no evidence of disease. 
Clinicopathologic characteristics of the 25 patients without 
recurrence and 11 additional patients with metastatic 
spread are listed in Supplementary Table 1.
Histopathology
Histologically, the majority of primary ACCs 
(9/11) displayed tubulocribriform growth patterns with 
dual populations of luminal and abluminal cells, whereas 
two cases were of solid type (Figure 2A, 2B). The 
growth pattern between primary tumors and metastases 
was preserved in all but one case in which the primary 
tumor was tubulocribriform and some of the multiple 
metastases were of solid type (case 6) (Table 1) (Figure 
2C, 2D). Immunohistochemically, all primary ACCs and 
metastases were positive for CK7, CD117, and MYB 
(Figure 3B, insert) and consistently negative for CK20 and 
neuroendocrine markers (CD56, chromogranin A). Dual 
TTF-1 and napsin A positivity was focal in pulmonary 
metastases of two cases. Ki-67 indices in primary 
tumors and metastases ranged from 5–60% (median: 
10). All immunohistochemical results are summarized in 
Supplementary Table 2.
FISH
In all cases, the pattern of MYB and NFIB aberrations 
was identical between primary ACC and metastasis (Table 
2). In 4/10 patients, concurrent rearrangements of MYB 
and NFIB were identified (Figure 3A, 3B). In the majority 
of tumor cells, the MYB break-apart probe showed a 
green/red signal ratio of 3 in case 3 and a red/green signal 
ratio of 3 in case 6, consistent with amplification of the 5′ 
and 3′ parts of MYB, respectively (Figure 3C). Four cases 
with MYB protein expression did not harbor identifiable 
alterations in MYB (Figure 3B, insert and Table 2). MYBL1 
was intact in all cases (not shown).
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Targeted next-generation sequencing of primary 
and metastatic tumor tissue
Point mutations in primary and metastatic ACC 
was assessed using a targeted NGS panel covering 
approximately 2,800 mutational hotspots in 50 cancer-
related oncogenes and tumor-supressor genes. Truncal 
mutations present in both primary tumor and metastasis 
were identified in case 1 (NRAS, NOTCH1), case 4 
(BRAF, TP53), and case 11 (APC). In wild-type primary 
tumors, metastases showed single mutations in case 3 
(NRAS), case 6 (PIK3CA in lung metastasis and BRAF 
in liver metastasis), and case 8 (HRAS) (Table 3). Loss 
of mutations from primary tumor to metastases were 
Figure 1: Anatomical localization of primary salivary gland adenoid cystic carcinomas and distant metastases. (A) 
Primary adenoid cystic carcinomas were located to the major and minor salivary glands of the head and neck. Distant metastases were 
located to the brain (n = 1), lungs (n = 8), and liver (n = 3). (B) Positron emission tomography – computerized tomography (PET-CT) scan 
of case 6 with metachronous metastases to the hilar region of the left lung and liver (red arrows). (C) CT-scan of the same patient showing 
the pulmonary and (D) hepatic metastases.
Table 1: Clinicopathologic characteristics at diagnosis of primary and metastatic adenoid cystic carcinoma
Case Age/Sex
Site of 
primary RT Histology
TNM at 
diagnosis
Stage at 
diagnosis Radical
Time to 
metastasis, 
months
Site of 
metastasis Histology Radical
Outcome, 
months^
1 47/M Submandibular + S T1N1M0 I No 119 Brain S No DOD, 2
2 53/M Submandibular + TC T1N0M0 I No 52 Lung TC Yes NED, 19
3 53/M Submandibular + TC T2N3M0 IVB No 11 Lung TC No DOD, 3
4 57/M Base of tongue + TC T3N0M0 III No 7 Lung TC Yes AWD, 36
5 36/F Hard palate + TC T1N0M0 I No 69 Lung TC Yes DOD, 90
6 58/F Sinus + TC T2N0M0 II No 107
114
Liver
Lung
S/TC*
TC
Yes
Yes
AWD, 26
7 49/M Base of tongue + TC T3N0M0 III No 45 Lung TC Yes DOD, 46
8 67/M Parotid + S T2N0M0 II Yes 9 Lung S Yes DOD, 73
9 63/F Parotid + TC T4aN0M0 IVA Yes 68 Lung TC Yes NED, 75
10 59/F Parotid + TC T2N0M0 II Yes 102 Liver TC Yes AWD, 97
11 62/F Sublingual + TC T2N1M0 III Yes 53 Liver TC Yes NED, 52
^After diagnosis of metastatic disease. *multiple metastases of which some were solid and others tubulocribriform. RT = radiotherapy; S = solid; TC = 
tubulocribriform; DOD = Dead of disease; NED = No evidence of disease; AWD = Alive with disease.
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identified in case 5 (PDGFRA) and case 9 (FGFR2). No 
mutations were identified in 6/11 (54.5%) of primary 
ACCs and three of these had no mutations in the 
metastatic lesions. In order to account for patient-specific 
single nucleotide polymorphisms (SNPs), matched normal 
salivary gland tissue was sequenced from the seven cases 
with this material available. This did not exclude any of 
the mutations identified in neither primary ACCs or distant 
metastases.
MicroRNA expression profiling of primary and 
metastatic tumor tissue
Comparing miRNA expressions of primary 
ACC and normal salivary gland tissue identified one 
upregulated (hsa-miR-1271-5p) and 7 downregulated 
(hsa-miR-1199-3p; hsa-mir-6865; hsa-miR-4717-5p; 
hsa-mir-610; hsa-miR-6878-5p; hsa-mir-519e; hsa-
miR-5572) miRNAs (false discovery rate [FDR] < 
0.05). Comparing metastases and normal salivary gland 
tissue, we identified 4 upregulated (hsa-miR-922; hsa-
miR-1271-3p; hsa-mir-6790; hsa-miR-6894-3p) and 7 
downregulated (hsa-mir-6865; hsa-miR-1199-3p; hsa-
miR-4717-5p; hsa-miR-499a-5p; hsa-miR-4790-5p; hsa-
mir-3936; hsa-mir-127) miRNAs (FDR < 0.05) (Figure 4). 
Among these, hsa-miR-1199-3p, hsa-mir-6865, and hsa-
miR-4717-5p were downregulated in primary tumors 
as well as metastases as compared to normal salivary 
gland tissue. Functional annotation of the differentially 
expressed miRNAs between primary ACC and normal 
salivary gland tissue and between metastases and normal 
salivary gland tissue identified their involvement in 
regulating genes in several Kyoto Encyclopedia of 
Genes and Genomes (KEGG) categories, including 
metabolism, migration, and signal transduction 
pathways (Supplementary Tables 3 and 4). When 
comparing primary ACCs and metastases as groups, 
there were no significantly differentially expressed 
miRNAs. Hierarchical clustering including primary 
and metastatic ACC as well as normal salivary gland 
tissue placed normal salivary gland together, with the 
dendrogram including all but one specimen (Figure 5). 
Primary and metastatic lesions were scattered in the 
left main cluster and only in one patient (case 7) did the 
primary tumor and metastasis cluster together (Figure 5). 
Repeating the analysis including only primary ACC and 
metastases and re-normalizing data, there was still no 
difference (FDR > 0.05) but hierarchical clustering by 
a p < 0.01 cut-off for differential expression placed all 
metastases in one main cluster of the dendrogram and 
10/11 primary ACCs in the other main cluster (Figure 
6). Resampling did not identify significant differences 
between the clusters with or without the inclusion of 
normal salivary gland tissue, but normal salivary gland 
tissue separated with the highest values (Supplementary 
Figures 1 and 2).
Figure 2: Histological features of primary and metastatic salivary gland adenoid cystic carcinoma. (A) Adenoid cystic 
carcinoma of the sinonasal minor salivary glands with tubular and cribriform areas and accumulation of basophilic basal membrane 
material in pseudoluminae (case 6) (hematoxylin & eosin, H&E). (B) Adenoid cystic carcinoma of the submandibular gland from case 
1 with solid aggregates of basaloid tumor cells. Nuclei are large and mitoses are frequent (H&E). (C) Pulmonary metastasis of a well-
differentiated tubulocribriform adenoid cystic carcinoma from the primary tumor in (A). Normal lung parenchyma is seen to the right 
(asterisk) (H&E). (D) Hepatic metastasis showing a solid adenoid cystic carcinoma. This specimen is from the same patient as in (A and 
C). Normal liver parenchyma is seen to the right (asterisk) (H&E). Scale bar = 100 μm.
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MicroRNA expression profiling of primary 
tumors from patients with and without 
subsequent recurrence
When comparing the miRNA expression of the 
primary ACCs along with 11 additional patients who 
subsequently developed metastases (total n = 22) 
and primary ACCs from patients who remained free 
of metastases (n = 25), no miRNA was differentially 
expressed at FDR < 0.05. 
DISCUSSION
The clinical course of patients with ACC is 
unpredictable and once metastatic disease presents, the 
treatment options are limited as surgical resection is far 
from always curative and effective targeted treatments 
are lacking [16, 17]. These features are illustrated in the 
series presented here as 3/11 patients with subsequent 
metastatic disease were initially diagnosed with only 
stage I disease, 5/11 patients died of metastatic disease 
Figure 3: Rearrangements and copy number status of MYB and NFIB in primary and metastatic adenoid cystic 
carcinoma. Fluorescence in situ hybridization with break-apart probes showing split signals of the green centromeric (arrowheads) and 
red telomeric (arrows) for (A) MYB and (B) NFIB in a pulmonary metastasis. (B, insert) Representative area of the primary tumor in case 
5 showing diffuse positivity for MYB protein despite being without detectable MYB abnormalities. (C, upper left) MYB break-apart probe 
showing isolated amplification of the green centromeric probe (arrowheads, case 3) and (C, upper right) red telomeric probe (arrows, case 
6). (C, bottom) Schematic presentation of the chromosomal location of the break-apart probe. Multiple green and red signals are consistent 
with isolated amplification of the 5′ and 3′ parts of the MYB gene, respectively. Image is not drawn to scale.
Table 2: Rearrangement of MYB and NFIB in primary adenoid cystic carcinoma and metastases
Case Primary adenoid cystic carcinoma Metastatic adenoid cystic carcinoma
1 MYB-NFIB MYB-NFIB
2 Normal Normal
3 MYB amplification1 MYB amplification1
4 MYB-NFIB MYB-NFIB
5 Normal Normal
6
MYB amplification2
Liver
MYB amplification2
Lung
MYB amplification2
7 MYB-NFIB MYB-NFIB
8 MYB-NFIB MYB-NFIB
9
Normal
Lung3
Normal
Lung3
Normal
10 Not available Not available
11 Normal Normal
All patients had intact MYBL1 genes.1Multiple green signals per nucleus, consistent with 5′ amplification. 2Multiple red signals 
per nucleus, consistent with 3′ amplification. 3Separate tubulocribriform metastases from right and left lung, respectively.
Oncotarget19680www.oncotarget.com
within the follow-up period, and 3/11 experienced 
additional distant recurrence following otherwise complete 
metastasectomies (Table 1).
Over recent decades, genetics has continued to 
provide insights into the causes of human cancer through 
the identification of genetic aberrations underlying 
different malignant phenotypes. But while some cancers 
are heterogeneous in their genetic background, the 
identification of recurrent genetic alterations in several 
types of salivary gland tumors has greatly increased 
the understanding of these relatively rare entities [18]. 
In ACC, NOTCH1 mutations have been shown to be 
enriched in recurrent and metastatic tumors and mutations 
in NOTCH pathway genes characterize a small subset of 
cases with solid histology and a particularly aggressive 
clinical course [19, 20]. Aside from this, genetics has 
otherwise not contributed to an understanding of the main 
cause of ACC mortality, i.e. metastatic spread. Recurrent 
Figure 4: Venn diagram showing differentially expressed microRNAs between normal salivary gland tissue as 
compared to primary and metastatic adenoid cystic carcinoma. Eight miRNAs were differentially expressed between normal 
salivary gland tissue and primary adenoid cystic carcinoma, and 11 miRNAs were differentially expressed between normal salivary gland 
tissue and distant metastases. Three miRNAs were downregulated in both tumor tissues (underlined). There was no difference between 
primary tumor and metastases, and therefore all miRNAs investigated were mutual.
Table 3: Hotspot mutations in paired primary and metastatic salivary gland adenoid cystic carcinoma 
Case
Normal salivary gland Primary adenoid cystic carcinoma Metastasis
Mutation Location Gene Nucleotide change (frequency)
Amino acid 
change Location Gene
Nucleotide change 
(frequency) Amino acid change
1 No mutation Submandibular NRAS
NOTCH1
TP53
c.35G>A (7.4)
c.7408delT (48.4)
818G>A (11.3)
p.G12D#
p.S2470fs*7
p.R273H#
Brain NRAS
NOTCH1
c.35G>A (47.1)
c.7408delT (41.5)
p.G12D#
p.S2470fs*7
2 No mutation Submandibular WT Lung WT
3 No mutation Submandibular WT Lung NRAS c.35G>A (35.8) p.G12D#
4 - Base of tongue BRAF
TP53
c.1742A>T (44.6)
c.844C>T (44.1)
p.N581I#
p.R282W#
Lung BRAF
TP53
c.1742A>T (33)
c.844C>T (35.5)
p.N581I#
p.R282W#
5 - Hard palate PDGFRA c.2546A>G (9.3) p.Y849C Lung WT
6 - Sinus WT Lung PIK3CA c.1624G>A (31.9) p.E542K#
Liver BRAF c.1780G>A (47.2) p.D594N#
7 - Base of tongue WT Lung WT
8 No mutation Parotid WT Lung HRAS c.37G>C (44.8) p.G13R#
9 No mutation Parotid FGFR2 c.1150G>A (11.5) p.G384R LungR1 WT
LungL1 WT
10 No mutation Sublingual WT Liver WT
11 No mutation Parotid APC c.3313C>T (51.2) p.R1105W Liver APC c.3313C>T (53.2) p.R1105W
1Separate tubulocribriform metastases from right and left lung, respectively. #Recurrent oncogenic hotspot mutation.
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gene fusions involving MYB, MYBL1, and NFIB are 
hallmarks of ACC, and we demonstrate the preservation 
of MYB and NFIB rearrangements between the primary 
ACC and the metastases, consistent with the fundamental 
role of these genes in ACC formation [11]. Interestingly, 
we found amplification of the 3′ as well as 5′ parts of 
MYB (case 6 and 3, respectively) which were retained in 
the metastatic cells. While the 5′ part of the MYB gene 
hosts the DNA binding and transactivation domains, the 3′ 
part of MYB hosts the negative regulatory domain that is 
consistently lost in the MYB-NFIB fusion [21]. Therefore, 
amplification of the 5′ part of MYB in case 3 goes well in 
hand with the oncogenic properties of this part of the MYB 
gene, while the significance of isolated amplification of 
the 3′ part of MYB in case 6 is unclear. Also, we found 
diffuse expression of MYB protein in all cases, including 
those without abnormalities of MYB as characterized with 
FISH, which further underline the importance of this 
protein in ACC biology (Figure 3B). While elucidating 
the mechanism responsible for MYB overexpression is 
beyond the scope of this study, others have shown the 
translocation of various super-enhancer sequences to result 
in MYB overexpression [8].
Targeted treatment directed by cancer genomics 
face substantial complexity with the concept of 
intratumoral heterogeneity, and a study by Liu et al. 
demonstrated this phenomenon in ACC, although to a 
low extent as compared to other carcinomas [11, 22]. 
Additional complexity arises when also considering 
the metastatic compartment of malignant disease, but 
accounting for this is of paramount importance, since 
eradication of this cell population is a prerequisite for a 
sustainable effect of targeted treatment [22]. Liu et al. 
demonstrated that mutations exclusive for metastatic 
lesions (mainly lymph node metastases) were indeed 
present in ACC, and to a lesser extent in synchronous 
as compared to metachronous metastases [11]. In the 
present study, all metastases were metachronous and most 
were located at the clinically most relevant anatomical 
sites for ACC patients, i.e. lung and liver. Using targeted 
next-generation sequencing, we identified mutations 
exclusive for the metastatic lesions in 3/11 patients 
but also mutations exclusive for the primary lesions in 
another three patients (Table 3). While mutations found 
exclusively in the metastatic lesions of case 3, 6, and 
8 could represent mutations involved in the metastatic 
Figure 5: Heatmap of microRNA expression in primary adenoid cystic carcinoma, metastatic adenoid cystic carcinoma, 
and normal salivary gland tissue. Normal salivary gland tissue is clustered to the right. No difference in microRNA expression was 
found between primary tumors and metastases. In the dendrogram, primary tumors and corresponding metastases were only highly similar 
in case 7. There was no clustering of cases according to gene fusion status.
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phenotype, the significance of the mutations found 
exclusively in the primary lesions of case 1, 5, and 9 are 
more likely to be passenger mutations (Table 3). This 
latter statement is supported by the low frequencies of 
these mutations (9.3–11.5%). Although the degree of 
intratumoral heterogeneity in ACC has been shown to be 
present only to a minor extent, it must be noted that our 
results rests on the repertoire of mutations identified in 
1mm tumor biopsies and not the entire tumor. Therefore, 
it is possible that the frequencies of different mutations 
could differ in other areas of the same tumor. In the cases 
with mutations found exclusively in the metastatic lesions 
these mutations were all present in high frequencies, but 
it is not unlikely that the same mutation could be found 
in the primary lesion, although probably at a lower 
frequency, if another region had been sampled. Therefore, 
although we employed a targeted sequencing panel, we 
confirmed the heterogeneous genomic landscape of 
paired primary and metastatic ACC. However, in contrast 
to the tumor-defining oncogenic driver function of 
ACC gene fusions, interpreting the significance of point 
mutations in ACC is not an easy task. This is exemplified 
by a comparison of our findings with datasets from 207 
primary salivary gland ACCs and 7 ACC metastases 
from cBioPortal [23]. In this dataset, mutations in APC, 
FGFR2, HRAS, PIK3CA, and TP53 were previously 
reported but were all different from the mutations we 
found in our material (Supplementary Table 5). However, 
in accordance with previous studies, mutations in 
NOTCH1 tended to cluster in the proline-glutamic acid-
serine-threonine (PEST) domain, similar to the activating 
mutations in T-cell acute lymphoblastic leukaemia 
(Supplementary Table 5) [11, 19, 20, 24]. Furthermore, 
demonstrating the diversity of the mutational repertoire 
involved in the metastatic process is the identification 
of distinctly different oncogenic hotspot mutations in 
the lung and liver metastases in case 6. Importantly, the 
PIK3CA in case 6 and NRAS in case 1 and 3 are rational 
candidates for off-label targeted treatments and the 
NOTCH1 mutation in case 1 is eligible for inclusion in an 
ongoing clinical trial for advanced salivary gland cancers 
(clinicaltrials.gov identifier: NCT020697309) (Table 3). 
Collectively, this underscores the need for extensive 
sampling of ACC patients in the context of clinical trials.
Figure 6: Heatmap of microRNA expression in primary adenoid cystic carcinoma and metastatic adenoid cystic 
carcinoma. The right main cluster consisted of 10/11 primary salivary gland adenoid cystic carcinoma. The left main cluster included 
11/11 metastases and the remaining primary tumor. P-value < 0.01, FDR > 0.05.
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While genetics explains the events leading to ACC 
formation mainly in the form of fusion genes, the low 
rate of mutations exclusive for the metastatic lesions 
presented here makes alternative biological mechanisms 
likely to be involved. As previous in vitro studies on the 
involvement of miRNA in the metastatic progression of 
ACC has been hampered by cross-contamination, data 
from human samples has not been available until now 
[15]. By global miRNA expression profiling we identified 
miRNAs differentially expressed between primary ACC 
and metastases as compared to normal salivary gland 
tissue but no difference between primary and metastatic 
lesions (Figure 4). Some of these miRNAs were exclusive 
for primary and metastatic ACCs, but three poorly 
characterized miRNAs were downregulated in both groups 
(Figure 4). The significance of these three miRNAs is 
currently uncertain. Interestingly, functional annotation 
showed the miRNAs dysregulated in metastases to target 
genes involved in functions of key importance for the 
metastatic phenotype, with the most significant function 
being extracellular molecule interaction (Supplementary 
Table 4). Normal salivary gland tissue separated from 
ACC in hierarchical clustering but primary ACCs and 
metastases were intermingled, with only one case having 
primary tumor and metastasis placed adjacently (Figure 
5 and Supplementary Figure 1). Although this gives an 
impression of primary tumors and metastases being 
similar, the inclusion of three different groups with a 
relatively low number of samples could obscure possible 
patterns. Although not reaching statistical significance, 
there was a near complete separation between primary 
ACC and metastases when normal salivary gland 
tissue was left out of the clustering analysis (Figure 6). 
Functional annotation of the miRNAs in Figure 6 identify 
these to be involved in a large number of metabolic 
functions, signaling pathways, and as being involved in 
other types of cancer (Supplementary Table 6). While this 
finding is intriguing, it must be interpreted with caution 
as it still relies on non-significant differences and needs 
further validation. Alternatively, given the highly diverse 
spectrum of somatic mutations in ACC shown here as 
well as in other studies, it is possible that ACC is a mainly 
fusion-driven disease with otherwise diverse molecular 
changes separating primary and metastatic lesions, 
including miRNA expression [7, 11, 18, 19, 22].
The acquirement of different somatic mutations on top 
of the MYB-NFIB fusion has been demonstrated to occur 
during high-grade transformation of breast ACC, which also 
included mutations in NOTCH1 and FGFR1 [25]. Also in 
breast cancer, remarkably similar miRNA and global gene 
expression profiles have been found between paired primary 
breast carcinoma and metastases [26, 27]. In one study these 
findings extended so far that primary tumors were as similar 
to their metastases as repeated sampling from the primary 
tumor, suggesting that the metastatic capability was an 
inherent feature of the primary tumor and not something 
unique for the metastatic lesion [27–29]. If this was also the 
case in salivary gland ACC, this could imply that patients 
developing metastases had primary tumors that were 
inherently more “metastatis-like”. Since this would make 
our comparison of paired primary ACC and metastases 
futile, we compared the miRNA expression profile of 
primary ACCs with and without subsequent development of 
recurrent disease and found no difference in their miRNA 
expression. This implies that primary ACCs are similar in 
miRNA expression irrespective of later development of 
metastases. In direct extension of this consideration it is 
noteworthy that only the present material of ACC metastases 
has undergone miRNA expressional profiling, and that 
comprehensive genetic and miRNA expressional profiling of 
additional metastatic lesions will extend the understanding 
of the biological underpinnings of this relatively rare disease.
The complexity in providing a complete molecular 
landscape of the metastatic process in ACC gives rise 
to some limitations in our study. Sampling of multiple 
tumor regions would allow for more solid statements to 
be made regarding tumor heterogeneity, which would be 
further strengthened by the use of a more comprehensive 
sequencing platform for the detection of mutational 
diversity. Due to the lack of significance between primary 
and metastatic lesions, the clustering based on miRNA 
expression may not necessarily reflect the underlying 
biology, but the rarity of ACCs with available primary 
and metastatic tissue dictated the sample size which is an 
inherent limitation to the study of rare diseases.
In conclusion, we present a series of paired primary 
and metastatic salivary gland ACCs and demonstrate the 
preservation of MYB and NFIB aberrations during the course 
of metastatic progression. Contrasting with the fundamental 
role of these two genes in ACC, no general pattern of 
somatic mutations or significant changes in miRNA 
expression was found in metastatic lesions. Although larger 
materials could assist in delineating these issues further, our 
findings support the metastatic process in ACC as being a 
complex and heterogeneous biological phenomenon.
MATERIALS AND METHODS
Patient material
Patients surgically treated for salivary gland ACC 
and resected metastatic lesion were identified in the Danish 
Pathology Data Bank (Patobank). Eleven patients with both 
tissues available were identified, and formalin-fixed and 
paraffin-embedded (FFPE) specimens were collected from 
pathology departments all over Denmark. In seven cases, 
triplet material from primary ACC, metastatic ACC, and 
normal salivary gland tissue was available. In the remaining 
four cases only the primary and metastatic tumors were 
available. For the analysis of miRNA expression in primary 
tumors only, 11 additional ACCs with subsequent metastases 
were included along with 25 ACCs that remained free of 
Oncotarget19684www.oncotarget.com
recurrence. Median follow-up periods for patients with and 
without subsequent distant failure were 78 months (range: 
14–233) and 154 months (range: 72–322), respectively 
(Supplementary Table 1). None of the patients had received 
radiotherapy or chemotherapy prior to surgery or biopsy. All 
cases were reviewed by a head and neck pathologist (TKA) 
[30–32]. The Regional Ethics Committee (H-6-2014-086) 
and the Danish Data Protection Agency (REG-94-2014) 
approved this study.
Immunohistochemistry
FFPE blocks were sectioned and mounted on coated 
slides (Dako, Glostrup, Denmark) and stained with H&E 
according to standard protocols. Tumor sections were 
deparaffinized using EZ-prep (Ventana Medical Systems®, 
Tucson, AZ, USA) and immunohistochemistry was 
performed using the Ventana Benchmark Ultra platform 
(Ventana Medical Systems) as previously described 
[33]. The following primary antibodies were employed: 
CD117 (polyclonal, 1:100, Dako (Glostrup, Denmark)), 
CD56 (clone 1B6, 1:50, Novocastra (Newcastle, UK)), 
chromogranin A (polyclonal, 1:2000, Dako), CK7 (clone 
OV-TL 12/30),1:1000, Dako), CK20 (clone KS20.8, 1:400, 
Dako), ki-67 (clone MIB1, 1:100, Dako), MYB (clone 
EP769Y 1:150 (AbCam, Cambridge, UK), napsin A (clone 
IP64, 1:400, Novocastra), and TTF-1(clone SPT24, 1:100, 
Novocastra). MYB was considered positive when nuclear 
staining was observed in at least 5% of tumor cells [31]. 
Positive controls as suggested on datasheets were used. 
Negative controls omitting the primary antibody were 
performed for all antibodies.
Fluorescence in situ hybridization
Primary tumor and metastatic lesion were evaluated 
for rearrangements of MYB (Empire Genomics, Buffalo, 
NY, USA), MYBL1 (Empire Genomics), and NFIB (Empire 
Genomics) genes with break-apart probes according to the 
manufacturer’s instructions using the HYBrite platform 
(Abbott Molecular) and counterstained with DAPI II 
(ZytoVision GmbH, Bremerhaven, Germany) as previously 
described [31]. One hundred nuclei were counted, and 
only nuclei where the entire nuclear membrane could be 
visualized were scored. Break-apart signals in ≥ 10% of 
cells was considered to represent rearrangement [31]. 
Amplification was defined as a red/green or green/
red signal ratios ≥ 2 signals for 3′ and 5′ amplification, 
respectively. Amplification was defined as a red/green or 
green/red signal ratio of  ≥ 3 in in more than 10% of tumor 
cells for 3′ and 5′ amplification, respectively.
DNA extraction and targeted next-generation 
sequencing
DNA was extracted from one 1 mm core obtained 
from the original FFPE block after identification of a 
representative tumor area from an H&E slide in order to 
minimize admixture of stromal cells and consequently 
a high tumor cell content, as previously described [34]. 
Briefly, targeted NGS was carried out on the Ion PGM™ 
System (Thermo Fisher Scientific, Walham, MA, USA) 
with the Ion AmpliSeq Cancer Hotspot Panel version 2 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. The Ion AmpliSeq Cancer Hotspot Panel 
v.2 covers approximately 2,800 mutational hotspots in 
50 cancer-related oncogenes and tumor-supressor genes. 
Library preparation was performed from 10 ng of purified 
DNA using Ion AmpliSeq Library kit 2.0 according to 
manufacturer’s instructions (Thermo Fisher Scientific) 
and using the Ion PGM Hi-Q view kit (Thermo Fisher 
Scientific) as template kit for the IonChef (Thermo 
Fisher Scientific). Sequencing was carried out using 
Ion PGM Hi-Q view Sequencing kit with the Ion 316™ 
Chip v2 (Thermo Fisher Scientific). Median number of 
mapped reads in normal salivary gland, primary tumor, 
and metastasis were 296,709, 215,455, and 468,226, 
respectively. Median allele coverage in normal salivary 
gland, primary tumor, and metastasis were 1,286, 735, 
and 2,097, respectively. Sequencing statistics are given 
for each sample in Supplementary Table 7. Variant 
calling was conducted using the Torrent Variant Caller 
v4.6 of the Torrent Suite™ Software (Thermo Fisher 
Scientific) using default settings. Variants were evaluated 
according to the American College of Medical Genetics 
and Genomics (ACMG) guidelines using the ClinVar 
database (https://www.ncbi.nlm.nih.gov/clinvar/docs/
acmg/), COSMIC (http://cancer.sanger.ac.uk/cosmic), 
and by literature search (https://www.ncbi.nlm.nih.gov/
pubmed) [35]. Mutant reads were not allowed in the 
normal tissue. A mutation frequency of 5%, with equal 
± strand distribution, was regarded as mutation positive 
given that DNA was extracted from cores and not whole 
sections.
RNA extraction
RNA was extracted from one 1mm core as described 
above. In case 9, only one pulmonary metastasis had 
sufficient tissue left. The QiaCube (Qiagen, Valencia, 
CA, USA) was used for automated isolation of miRNA 
with the miRNeasy FFPE Kit (Qiagen) according to the 
manufacturer’s instructions [36]. Total RNA concentration 
was measured using the NanoDrop ND-1000 (Thermo 
Scientific, Wilmington, DE, USA) and ranged from 366–
1536 ng/μl with A260/A280 ratio ranging from 1.8–2.6, 
indicating high nucleic acid purity.
MicroRNA array
The Affymetrix miRNA 4.1 array platform 
(Affymetrix, Santa Clara, CA, USA) was used, covering 
all entries in Sanger miRbase database v.20, including 
2,578 mature and 2,025 immature human miRNAs with 
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a dynamic range of 4 logs. For miRNA analysis, 300 
μg of total RNA was labelled with the FlashTag Biotin 
HSR RNA Labelling kit (Affymetrix) according to the 
manufacturer’s instructions. All cases were run in a 
single batch to avoid batch variation. Array plates were 
washed, stained, and scanned on the GeneTitan Instrument 
(Affymetrix). Raw data are available from the journal 
website as Supplementary Table 8.
MicroRNA data analysis
The raw miRNA expression data was normalized 
using the quantile normalization using the free R package 
preprocessCore [37]. The normalized data was log 
transformed with base 2 to ensure normal or approximately 
normal distribution before statistical modelling. 
Considering the fact that multiple samples (normal 
salivary gland tissue, primary ACC and metastases) were 
taken from each patient, we fitted the linear mixed-effect 
models with miRNA expression levels as the dependent 
variable, sample grouping (normal, primary, metastasis) 
as the fixed effect variable, and patient ID as the random 
effect variable. In fitting the models, normal tissue was 
defined as the reference group. The mixed-effect models 
were fitted using the R package lmerTest. Differential 
expression analysis of primary tumors from patients with 
and without subsequent metastases was done by fitting 
a regression model that regresses miRNA expression on 
metastasis status equivalent to a student t-test. P values 
from the statistical analysis were adjusted for multiple 
testing by calculating the FDR using the R function 
p.adjust() defining method=”fdr” [38]. The R scripts used 
for data analysis are available upon request. We applied 
clustering analysis on the significant miRNAs using the 
heatmap.2 function in the R package gplots. The default 
distance algorithm set as “Euclidean” distance was used 
to compute the distances between clusters. The miRNAs 
with FDR < 0.05 were defined as statistically significant. 
Bootstrap resampling was used to generate probability 
values as implemented in pvclust [39]. 
Pathway analysis and functional annotation
Pathway analysis of miRNAs was performed with 
DIANA-miRPath v3.0 software available from http://
snf-515788.vm.okeanos.grnet.gr/ [40]. The DIANA-
TarBase v7.0 was selected as the miRNAtarget prediction 
algorithm [41]. For functional annotation, the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways 
were used and enrichment score for KEGG pathways 
presented by –ln (p value) [42].
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